A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer.

Trial Profile

A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2015

At a glance

  • Drugs Masitinib (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors AB Science
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 09 Apr 2015 According to AB Science media release, results published in the journal Annals of Oncology.
    • 09 Apr 2015 Results (Subgroup analysis) published in the AB Science Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top